Louisiana State Employees Retirement System Sells 400 Shares of Cencora, Inc. (NYSE:COR)

Louisiana State Employees Retirement System lessened its stake in Cencora, Inc. (NYSE:COR) by 4.1% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 9,400 shares of the company’s stock after selling 400 shares during the period. Louisiana State Employees Retirement System’s holdings in Cencora were worth $2,112,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Sylvest Advisors LLC bought a new stake in shares of Cencora in the 4th quarter valued at about $1,105,000. Insight Wealth Strategies LLC grew its position in shares of Cencora by 124.6% in the 4th quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company’s stock valued at $4,549,000 after buying an additional 11,232 shares during the last quarter. Cerity Partners LLC grew its position in shares of Cencora by 10.1% in the 3rd quarter. Cerity Partners LLC now owns 39,457 shares of the company’s stock valued at $8,881,000 after buying an additional 3,610 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. grew its position in shares of Cencora by 71.1% in the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 7,048 shares of the company’s stock valued at $1,583,000 after buying an additional 2,928 shares during the last quarter. Finally, Portfolio Design Labs LLC bought a new stake in shares of Cencora in the 3rd quarter valued at about $1,404,000. Institutional investors own 97.52% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on COR shares. JPMorgan Chase & Co. upped their price target on Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. Wells Fargo & Company boosted their price objective on Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 29th. Robert W. Baird boosted their price objective on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Mizuho initiated coverage on Cencora in a research note on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price objective on the stock. Finally, UBS Group boosted their price objective on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, Cencora has an average rating of “Moderate Buy” and an average price target of $277.90.

Cencora Stock Down 0.6 %

COR stock opened at $243.03 on Friday. The stock’s 50 day simple moving average is $238.70 and its 200 day simple moving average is $237.38. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $262.26. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.53 and a current ratio of 0.92. The company has a market cap of $46.97 billion, a P/E ratio of 34.57, a price-to-earnings-growth ratio of 1.49 and a beta of 0.49.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. On average, research analysts expect that Cencora, Inc. will post 15.36 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 3rd. Stockholders of record on Friday, February 14th will be paid a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.91%. The ex-dividend date is Friday, February 14th. Cencora’s dividend payout ratio (DPR) is presently 31.29%.

Insider Transactions at Cencora

In other news, Chairman Steven H. Collis sold 21,509 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total value of $5,208,619.44. Following the completion of the transaction, the chairman now directly owns 306,752 shares of the company’s stock, valued at $74,283,064.32. This represents a 6.55 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of the company’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the transaction, the executive vice president now directly owns 20,329 shares of the company’s stock, valued at approximately $4,649,648.88. This represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 73,187 shares of company stock valued at $17,790,912 over the last ninety days. 10.80% of the stock is currently owned by insiders.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.